Roy Jefferis

Summary

Affiliation: University of Birmingham
Country: UK

Publications

  1. ncbi request reprint Interaction sites on human IgG-Fc for FcgammaR: current models
    Roy Jefferis
    Division of Immunity and Infection, The Medical School, University of Birmingham, Edgbaston, Birmingham, UK
    Immunol Lett 82:57-65. 2002
  2. ncbi request reprint IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation
    R Jefferis
    Department of Immunology, Medical School, University of Birmingham, Edgbaston, UK
    Immunol Rev 163:59-76. 1998
  3. doi request reprint Glycosylation as a strategy to improve antibody-based therapeutics
    Roy Jefferis
    Division of Immunity and Infection, University of Birmingham, School of Medicine, Edgbaston, Birmingham, B15 2TT, UK
    Nat Rev Drug Discov 8:226-34. 2009
  4. ncbi request reprint Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I
    J Lund
    Department of Immunology, The Medical School, Birmingham, UK
    Eur J Biochem 267:7246-57. 2000
  5. ncbi request reprint Glycosylation of recombinant antibody therapeutics
    Royston Jefferis
    Division of Immunity and Infection, The School of Medicine, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    Biotechnol Prog 21:11-6. 2005
  6. doi request reprint Isotype and glycoform selection for antibody therapeutics
    Roy Jefferis
    University of Birmingham, Birmingham, UK
    Arch Biochem Biophys 526:159-66. 2012
  7. ncbi request reprint Antibody therapeutics: isotype and glycoform selection
    Roy Jefferis
    University of Birmingham, Division of Immunity and Infection, The School of Medicine, Edgbaston, Birmingham B15 2TT, UK
    Expert Opin Biol Ther 7:1401-13. 2007
  8. doi request reprint Aglycosylated antibodies and the methods of making and using them: WO2008030564
    Roy Jefferis
    Professor of Molecular Immunology University of Birmingham, Division of Immunity and Infection, B15 2TT UK
    Expert Opin Ther Pat 19:101-5. 2009
  9. ncbi request reprint The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs
    Roy Jefferis
    School of Immunity and Infection, The College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK
    Biotechnol Genet Eng Rev 26:1-42. 2010
  10. pmc Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis
    M Holland
    MRC Centre for Immune Regulation, The Medical School, University of Birmingham, UK
    Clin Exp Immunol 129:183-90. 2002

Collaborators

Detail Information

Publications22

  1. ncbi request reprint Interaction sites on human IgG-Fc for FcgammaR: current models
    Roy Jefferis
    Division of Immunity and Infection, The Medical School, University of Birmingham, Edgbaston, Birmingham, UK
    Immunol Lett 82:57-65. 2002
    ..This mini-review summarizes our current understanding of interactions of FcgammaRI, FcgammaRII and FcgammaRIII with human IgG antibodies. Particular emphasis is given to the influence of IgG-Fc glycosylation...
  2. ncbi request reprint IgG-Fc-mediated effector functions: molecular definition of interaction sites for effector ligands and the role of glycosylation
    R Jefferis
    Department of Immunology, Medical School, University of Birmingham, Edgbaston, UK
    Immunol Rev 163:59-76. 1998
    ....
  3. doi request reprint Glycosylation as a strategy to improve antibody-based therapeutics
    Roy Jefferis
    Division of Immunity and Infection, University of Birmingham, School of Medicine, Edgbaston, Birmingham, B15 2TT, UK
    Nat Rev Drug Discov 8:226-34. 2009
    ..This Review summarizes current knowledge of these methods and avenues for their exploitation in the clinic...
  4. ncbi request reprint Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I
    J Lund
    Department of Immunology, The Medical School, Birmingham, UK
    Eur J Biochem 267:7246-57. 2000
    ..Thus, the L243 scFvhCH2 homo-dimer constitutes the minimal truncated form that binds the MHC Class II antigen and triggers superoxide production through FcgammaRI...
  5. ncbi request reprint Glycosylation of recombinant antibody therapeutics
    Royston Jefferis
    Division of Immunity and Infection, The School of Medicine, University of Birmingham, Vincent Drive, Edgbaston, Birmingham B15 2TT, UK
    Biotechnol Prog 21:11-6. 2005
    ..Thus a further challenge will be the production of a second generation of antibody therapeutics customized for their clinical indication...
  6. doi request reprint Isotype and glycoform selection for antibody therapeutics
    Roy Jefferis
    University of Birmingham, Birmingham, UK
    Arch Biochem Biophys 526:159-66. 2012
    ..The FcγR and the C1q binding functions are dependent on glycosylation of the IgG-Fc. Normal human serum IgG is comprised of multiple glycoforms and biologic activities, other than catabolism, varies between glycoforms...
  7. ncbi request reprint Antibody therapeutics: isotype and glycoform selection
    Roy Jefferis
    University of Birmingham, Division of Immunity and Infection, The School of Medicine, Edgbaston, Birmingham B15 2TT, UK
    Expert Opin Biol Ther 7:1401-13. 2007
    ..Thus, when maximal antibody-dependent cell-mediated cytotoxicity activity is indicated a non-fucosylated IgG1 format may be optimal; when minimal activity is indicated an aglycosylated IgG2 may be the form of choice...
  8. doi request reprint Aglycosylated antibodies and the methods of making and using them: WO2008030564
    Roy Jefferis
    Professor of Molecular Immunology University of Birmingham, Division of Immunity and Infection, B15 2TT UK
    Expert Opin Ther Pat 19:101-5. 2009
    ..It remains to be demonstrated that such radical structural changes do not have a negative impact on the stability and immunogenicity of these constructs...
  9. ncbi request reprint The antibody paradigm: present and future development as a scaffold for biopharmaceutical drugs
    Roy Jefferis
    School of Immunity and Infection, The College of Medical and Dental Sciences, University of Birmingham, Edgbaston, Birmingham, UK
    Biotechnol Genet Eng Rev 26:1-42. 2010
    ....
  10. pmc Hypogalactosylation of serum IgG in patients with ANCA-associated systemic vasculitis
    M Holland
    MRC Centre for Immune Regulation, The Medical School, University of Birmingham, UK
    Clin Exp Immunol 129:183-90. 2002
    ..Both of these activities could impact on the processing and presentation of self-antigens in autoimmune disease...
  11. ncbi request reprint Glycosylation of natural and recombinant antibody molecules
    Roy Jefferis
    Immunity and Infection, University of Birmingham, B15 2TT UK
    Adv Exp Med Biol 564:143-8. 2005
  12. doi request reprint Glycosylation of antibody therapeutics: optimisation for purpose
    Roy Jefferis
    Immunity and Infection, University of Birmingham, UK
    Methods Mol Biol 483:223-38. 2009
    ..Advances in downstream processing also need to be realised whilst chemical changes during processing and storage must be minimised...
  13. ncbi request reprint Differential glycosylation of polyclonal IgG, IgG-Fc and IgG-Fab isolated from the sera of patients with ANCA-associated systemic vasculitis
    M Holland
    Division of Immunity and Infection, The Medical School, University of Birmingham, Edgbaston, UK
    Biochim Biophys Acta 1760:669-77. 2006
    ..Remarkably, this influence is exerted on all plasma cells. Interestingly, a licensed monoclonal antibody therapeutic, produced in Sp2/0 cells, is also shown to be hypogalactosylated in its IgG-Fc but fully galactosylated in its IgG-Fab...
  14. pmc No association between neutrophil FcgammaRIIa allelic polymorphism and anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis
    W Y Tse
    Department of Nephrology, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
    Clin Exp Immunol 117:198-205. 1999
    ..Our data suggest that the FcgammaRIIa receptor allotype is not a major factor predisposing to the development of ANCA+ systemic vasculitis, or to nephritis...
  15. pmc Neutrophil FcgammaRIIIb allelic polymorphism in anti-neutrophil cytoplasmic antibody (ANCA)-positive systemic vasculitis
    W Y Tse
    Department of Nephrology, Queen Elizabeth Hospital, and Department of Immunology, The Medical School, Birmingham University, Birmingham, UK
    Clin Exp Immunol 119:574-7. 2000
    ..The over-representation of the FcgammaRIIIb homozygous NA1 allele in patients with anti-MPO antibodies may have implications for disease susceptibility...
  16. ncbi request reprint Butyrate increases production of human chimeric IgG in CHO-K1 cells whilst maintaining function and glycoform profile
    Y Mimura
    Division of Immunity and Infection, The Medical School, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
    J Immunol Methods 247:205-16. 2001
    ..These results demonstrated that butyrate is of value for increasing the productivity of CHO-K1 for recombinant IgG and does not compromise either glycosylation or biological activity...
  17. ncbi request reprint Contrasting glycosylation profiles between Fab and Fc of a human IgG protein studied by electrospray ionization mass spectrometry
    Yusuke Mimura
    Division of Immunity and Infection, Medical School, Edgbaston, Birmingham, B15 2TT, UK
    J Immunol Methods 326:116-26. 2007
    ..Thus, combination of the two endoglycosidases can provide a simple means of glycan analysis of both Fab and Fc by ESI-MS, which may contribute to the development of therapeutic IgG with customized glycan profiles...
  18. pmc Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass
    M Holland
    MRC Centre for Immune Regulation, The Medical School, University of Birmingham, Birmingham, UK
    Clin Exp Immunol 138:183-92. 2004
    ....
  19. ncbi request reprint Role of oligosaccharide residues of IgG1-Fc in Fc gamma RIIb binding
    Y Mimura
    Division of Immunity and Infection, The Medical School, University of Birmingham, B15 2TT United Kingdom
    J Biol Chem 276:45539-47. 2001
    ..These results suggest that truncation of the oligosaccharides of IgG-Fc causes disorder and a closed disposition of the two C(H)2 domains, impairing sFc gamma RIIb binding...
  20. doi request reprint Development of a highly-sensitive multi-plex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine
    John P Campbell
    Clinical Immunology Service, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom
    J Immunol Methods 391:1-13. 2013
    ..Given the overall effectiveness of the anti-FLC mAbs, further clinical validation is now warranted on serial samples from a range of patients with B cell disorders. Use of these mAbs on other assay platforms should also be investigated...
  21. ncbi request reprint Site-specific glycosylation of an aglycosylated human IgG1-Fc antibody protein generates neoglycoproteins with enhanced function
    Gregory M Watt
    Complex Carbohydrate Research Center, The University of Georgia, 220 Riverbend Road, Athens, GA 30602, USA
    Chem Biol 10:807-14. 2003
    ..The neoglycoproteins displayed enhanced superoxide inhibition relative to aglycosylated Deltah-Fc N297C, where increased glycan size correlated positively with increased inhibition...
  22. pmc Chimeric antibodies to proteinase 3 of IgG1 and IgG3 subclasses induce different magnitudes of functional responses in neutrophils
    Rachel Colman
    Wellcome Trust Clinical Research Facility, University Hospital Birmingham Foundation Trust, Queen Elizabeth Hospital, Birmingham, UK
    Ann Rheum Dis 66:676-82. 2007
    ....